Aileron Therapeutics (ALRN) Scheduled to Post Earnings on Wednesday

Aileron Therapeutics (NASDAQ:ALRN) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 7th. Analysts expect Aileron Therapeutics to post earnings of ($0.58) per share for the quarter.

Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Tuesday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). On average, analysts expect Aileron Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aileron Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $2.36. 5,176 shares of the company’s stock were exchanged, compared to its average volume of 72,319. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.85 and a quick ratio of 5.85. Aileron Therapeutics has a 12 month low of $1.98 and a 12 month high of $13.61. The stock has a market cap of $33.75 million, a price-to-earnings ratio of -1.33 and a beta of -0.64.

In other Aileron Therapeutics news, major shareholder Bioventures Ltd Novartis sold 17,508 shares of the stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $2.10, for a total transaction of $36,766.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 56,962 shares of company stock worth $131,638. 16.10% of the stock is owned by company insiders.

Several research analysts have issued reports on the stock. ValuEngine upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Zacks Investment Research upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 13th.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Earnings History for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply